No, “clinical study” and “clinical trial” are not necessarily synonymous in the context of non-interventional studies in the EU.
In general, a clinical study refers to any investigation involving human participants that is intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal products, or to identify any adverse reactions to one or more medicinal products. This can include both (interventional) clinical trials and non-interventional studies.
A clinical trial, on the other hand, specifically refers to a type of interventional clinical study where one or more medicinal products are tested in human participants with the aim of evaluating their safety and/or efficacy i.e., there is a treatment intervention involving a medicinal product.
Non-interventional studies (NIS) are observational studies that do not involve any treatment interventions or protocol-dictated administration of a medicinal product. They are designed to observe patients in their natural clinical setting and collect data on the outcomes of a specific drug or treatment intervention.
So, while a clinical trial is a type of clinical study, not all clinical studies are clinical trials.
Revision 2 of ICH GCP caused confusion to those of us who work with non-interventional studies. The glossary claimed that a ‘clinical trial’ was synonymous with a ‘clinical study’ (Section 1.12 of ICH GCP(R2)). This works if you conduct clinical trials (they are a type of clinical study), but not if you conduct non-interventional studies, which are a type of ‘clinical study other than a clinical trial’ (Article 2.2(4) of Regulation EU/536/2014).
The (draft) Revision 3 of ICH GCP includes a new definition of ‘clinical trial’ provided in the Glossary, which removes any confusion regarding clinical trial vs clinical study.
Clinical Trial = Any interventional investigation in human participants intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s); and/or to identify any adverse reactions to an investigational product(s); and/or to study absorption, distribution, metabolism and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy.
Share this story...
Real World Evidence (RWE) 101 – SOPs and Regional Regulations
RWE 101 - SOPs and Regional Regulations In the realm of quality assurance (QA), it's vital that standard operating procedures (SOPs) are crafted in a way that accurately and [...]
Real World Evidence (RWE) 101 – Standard Operating Procedures
RWE 101 - Standard Operating Procedures Standard Operating Procedures (SOPs) are critical for the operation of any business, particularly in regulated industries like pharmaceuticals where precision, safety, and compliance [...]
Real World Evidence (RWE) 101 – Publications
RWE 101 - Publications The term RWE stands for Real-World Evidence, which is evidence derived from real-world data (RWD). RWD are data relating to patient health status and/or the [...]
Real World Evidence (RWE) 101 – Archiving Specifics
RWE 101 - Archiving Specifics Proper archiving of clinical study documents is an important practice for maintaining the quality, integrity, and usability of study data, and for ensuring regulatory [...]
Real World Evidence (RWE) 101 – Archiving Generics
RWE 101 - Archiving Generics In the context of health research, both observational studies and clinical trials are crucial for understanding disease processes, patient outcomes, and the safety and [...]
Real World Evidence (RWE) 101 – Study Close-out
RWE 101 - Study Close-Out Closing out an observational study involves several key steps to ensure that all study activities are concluded properly, and data integrity is maintained. Here [...]







